前列腺癌或乳腺癌高骨转移风险患者中18F-氟化钠PET-CT与99mTc骨显像联合SPECT的个体内比较(MITNEC-A1):一项多中心3期试验
MITNEC-A1是在加拿大十家医院开展的前瞻性、多中心、单队列3期试验,纳入288例高危前列腺癌或乳腺癌患者,个体内比较18F-NaF PET-CT与99mTc-MDP SPECT检测骨转移的准确性。在261例可分析患者中,18F-NaF PET-CT准确率84.3%,高于99mTc-MDP SPECT的77.4%,差异6.9%(P=0.016)。288例患者未报告不良事件。
要点
- 在261例可分析患者中,18F-NaF PET-CT总体准确率84.3%,99mTc-MDP SPECT为77.4%,差异6.9%(P=0.016)。
- 基于参考标准,261例患者中109例(42%)存在骨转移。
- 288例入组患者中未报告不良事件。
核心结论
- 18F-NaF有潜力取代99mTc-MDP成为高危前列腺癌或乳腺癌患者首选的骨显像放射性药物。
研究设计与样本
- MITNEC-A1为前瞻性、多中心、单队列3期试验,在加拿大十家医院开展。
- 纳入18岁及以上、WHO体能状态0-2分、高危或临床怀疑骨转移但无既往骨受累记录的前列腺癌或乳腺癌患者。
- 每位受试者在14天内分别完成18F-NaF PET-CT与99mTc-MDP SPECT检查,由两名独立阅片者在不知晓另一 modality 结果的情况下判读。
- 主要终点为符合方案人群中99mTc-MDP SPECT与18F-NaF PET-CT检测骨转移的总体准确率。
- 参考标准为组织病理学、临床和影像随访(最长24个月)的组合;安全性在所有入组患者中评估。
主要发现
- 2014年7月11日至2017年3月3日筛查290例,入组288例(乳腺癌64例,前列腺癌224例)。
- 261例同时接受18F-NaF PET-CT和99mTc-MDP SPECT并完成所需随访进入统计分析,中位随访735天(IQR 727-750)。
- 基于所用参考方法,261例中109例(42%)存在骨转移。
- 患者水平分析中,18F-NaF PET-CT准确率高于99mTc-MDP SPECT:84.3%(95%CI 79.9-88.7)vs 77.4%(95%CI 72.3-82.5),差异6.9%(95%CI 1.3-12.5),P=0.016。
- 288例入组患者中未报告不良事件。
关键数值与推荐
- 18F-NaF PET-CT患者水平总体准确率84.3%(95%CI 79.9-88.7)。
- 99mTc-MDP SPECT患者水平总体准确率77.4%(95%CI 72.3-82.5)。
- 两种方法准确率差异6.9%(95%CI 1.3-12.5),P=0.016。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Detection of skeletal metastases in patients with prostate cancer or breast cancer remains a major clinical challenge. We aimed to compare the diagnostic performance of 99mTc-methylene diphosphonate (99mTc-MDP) single-photon emission CT (SPECT) and 18F-sodium fluoride (18F-NaF) PET-CT for the detection of osseous metastases in patients with high-risk prostate or breast cancer. METHODS: MITNEC-A1 was a prospective, multicentre, single-cohort, phase 3 trial conducted in ten hospitals across Canada. Patients aged 18 years or older with breast or prostate cancer with a WHO performance status of 0-2 and with high risk or clinical suspicion for bone metastasis, but without previously documented bone involvement, were eligible. 18F-NaF PET-CT and 99mTc-MDP SPECT were done within 14 days of each other for each participant. Two independent reviewers interpreted each modality without knowledge of other imaging findings. The primary endpoint was the overall accuracy of 99mTc-MDP SPECT and 18F-NaF PET-CT scans for the detection of bone metastases in the per-protocol population. A combination of histopathological, clinical, and imaging follow-up for up to 24 months was used as the reference standard to assess the imaging results. Safety was assessed in all enrolled participants. This study is registered with ClinicalTrials.gov, NCT01930812, and is complete. FINDINGS: Between July 11, 2014, and March 3, 2017, 290 patients were screened, 288 of whom were enrolled (64 participants with breast cancer and 224 with prostate cancer). 261 participants underwent both 18F-NaF PET-CT and 99mTc-MDP SPECT and completed the required follow-up for statistical analysis. Median follow-up was 735 days (IQR 727-750). Based on the reference methods used, 109 (42%) of 261 patients had bone metastases. In the patient-based analysis, 18F-NaF PET-CT was more accurate than 99mTc-MDP SPECT (84·3% [95% CI 79·9-88·7] vs 77·4% [72·3-82·5], difference 6·9% [95% CI 1·3-12·5]; p=0·016). No adverse events were reported for the 288 patients recruited. INTERPRETATION: 18F-NaF has the potential to displace 99mTc-MDP as the bone imaging radiopharmaceutical of choice in patients with high-risk prostate or breast cancer. FUNDING: Canadian Institutes of Health Research.
引用
- Bénard F, Harsini S, Wilson D, et al. Intra-individual comparison of 18F-sodium fluoride PET-CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial. Lancet Oncol. 2022. PMID: 36343655. doi:10.1016/S1470-2045(22)00642-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。